FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2534429483> ?p ?o ?g. }

• W2534429483 endingPage "109" @default.
• W2534429483 startingPage "102" @default.
• W2534429483 abstract "•MAT9001 contains predominantly eicosapentaenoic acid (EPA) and docosapentaenoic acid. •Effects of MAT9001 vs EPA ethyl esters (-EE) in hypertriglyceridemia were tested. •MAT9001, compared with EPA-EE, produced larger triglyceride reductions. •MAT9001 also produced larger decreases in other lipoprotein-related variables. •These effects suggest MAT9001 might favorably alter cardiovascular risk. Background Long-chain omega-3 fatty acid concentrate pharmaceuticals are used in the United States for treatment of severe hypertriglyceridemia (≥500 mg/dL) and are under investigation as adjuncts to statins for lowering cardiovascular risk in patients with high triglycerides (TGs; 200–499 mg/dL). Objective To evaluate MAT9001, an investigational prescription-only omega-3 fatty acid agent containing predominantly eicosapentaenoic acid (EPA) and docosapentaenoic acid, in 42 men and women with fasting TG 200 to 400 mg/dL. Methods In this open-label, crossover trial, subjects received MAT9001 and EPA ethyl esters (EPA-EE) in random order. They were housed in a clinical research unit for 2 14-day treatment periods, separated by a ≥35-day washout. Lipoprotein lipids, apolipoproteins (Apos) and proprotein convertase subtilisin kexin type 9 levels were measured before and at the end of each treatment period. Results MAT9001, compared with EPA-EE, resulted in significantly (P < .05) larger reductions from pretreatment levels for TG (−33.2% vs −10.5%), total cholesterol (−9.0% vs −6.2%), non–high-density lipoprotein cholesterol (−8.8% vs −4.6%), very low–density lipoprotein cholesterol (−32.5% vs −8.1%), Apo C3 (−25.5% vs −5.0%), and proprotein convertase subtilisin kexin type 9 (−12.3% vs +8.8%). MAT9001 also produced a significantly (P = .003) larger reduction in Apo A1 (−15.3% vs −10.2%), but responses for high-density lipoprotein cholesterol (−11.3% vs −11.1%), low-density lipoprotein cholesterol (−2.4% vs −4.3%), and Apo B (−3.8% vs −0.7%), respectively, were not significantly different relative to EPA-EE. Conclusions MAT9001 produced significantly larger reductions than EPA-EE in several lipoprotein-related variables that would be expected to favorably alter cardiovascular disease risk in men and women with hypertriglyceridemia. Long-chain omega-3 fatty acid concentrate pharmaceuticals are used in the United States for treatment of severe hypertriglyceridemia (≥500 mg/dL) and are under investigation as adjuncts to statins for lowering cardiovascular risk in patients with high triglycerides (TGs; 200–499 mg/dL). To evaluate MAT9001, an investigational prescription-only omega-3 fatty acid agent containing predominantly eicosapentaenoic acid (EPA) and docosapentaenoic acid, in 42 men and women with fasting TG 200 to 400 mg/dL. In this open-label, crossover trial, subjects received MAT9001 and EPA ethyl esters (EPA-EE) in random order. They were housed in a clinical research unit for 2 14-day treatment periods, separated by a ≥35-day washout. Lipoprotein lipids, apolipoproteins (Apos) and proprotein convertase subtilisin kexin type 9 levels were measured before and at the end of each treatment period. MAT9001, compared with EPA-EE, resulted in significantly (P < .05) larger reductions from pretreatment levels for TG (−33.2% vs −10.5%), total cholesterol (−9.0% vs −6.2%), non–high-density lipoprotein cholesterol (−8.8% vs −4.6%), very low–density lipoprotein cholesterol (−32.5% vs −8.1%), Apo C3 (−25.5% vs −5.0%), and proprotein convertase subtilisin kexin type 9 (−12.3% vs +8.8%). MAT9001 also produced a significantly (P = .003) larger reduction in Apo A1 (−15.3% vs −10.2%), but responses for high-density lipoprotein cholesterol (−11.3% vs −11.1%), low-density lipoprotein cholesterol (−2.4% vs −4.3%), and Apo B (−3.8% vs −0.7%), respectively, were not significantly different relative to EPA-EE. MAT9001 produced significantly larger reductions than EPA-EE in several lipoprotein-related variables that would be expected to favorably alter cardiovascular disease risk in men and women with hypertriglyceridemia." @default.
• W2534429483 created "2016-10-28" @default.
• W2534429483 creator A5003493851 @default.
• W2534429483 creator A5032023438 @default.
• W2534429483 creator A5032531491 @default.
• W2534429483 creator A5053831963 @default.
• W2534429483 creator A5069899816 @default.
• W2534429483 date "2017-01-01" @default.
• W2534429483 modified "2023-10-09" @default.
• W2534429483 title "Effects of MAT9001 containing eicosapentaenoic acid and docosapentaenoic acid, compared to eicosapentaenoic acid ethyl esters, on triglycerides, lipoprotein cholesterol, and related variables" @default.
• W2534429483 cites W1721338807 @default.
• W2534429483 cites W1903949561 @default.
• W2534429483 cites W1985920370 @default.
• W2534429483 cites W1998826672 @default.
• W2534429483 cites W2005157832 @default.
• W2534429483 cites W2007576400 @default.
• W2534429483 cites W2008131041 @default.
• W2534429483 cites W2012632253 @default.
• W2534429483 cites W2020915011 @default.
• W2534429483 cites W2024196949 @default.
• W2534429483 cites W2024750102 @default.
• W2534429483 cites W2036747551 @default.
• W2534429483 cites W2048382309 @default.
• W2534429483 cites W2051470123 @default.
• W2534429483 cites W2057006290 @default.
• W2534429483 cites W2065501543 @default.
• W2534429483 cites W2066530607 @default.
• W2534429483 cites W2093598997 @default.
• W2534429483 cites W2099076206 @default.
• W2534429483 cites W2099767767 @default.
• W2534429483 cites W2102189298 @default.
• W2534429483 cites W2105604211 @default.
• W2534429483 cites W2116404316 @default.
• W2534429483 cites W2127059895 @default.
• W2534429483 cites W2130934099 @default.
• W2534429483 cites W2137722937 @default.
• W2534429483 cites W2138013532 @default.
• W2534429483 cites W2145692767 @default.
• W2534429483 cites W2156419944 @default.
• W2534429483 cites W2160957374 @default.
• W2534429483 cites W2168745915 @default.
• W2534429483 cites W2179627384 @default.
• W2534429483 cites W2182832918 @default.
• W2534429483 cites W2200388925 @default.
• W2534429483 cites W2236666692 @default.
• W2534429483 cites W784000521 @default.
• W2534429483 doi "https://doi.org/10.1016/j.jacl.2016.10.010" @default.
• W2534429483 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28391875" @default.
• W2534429483 hasPublicationYear "2017" @default.
• W2534429483 type Work @default.
• W2534429483 sameAs 2534429483 @default.
• W2534429483 citedByCount "15" @default.
• W2534429483 countsByYear W25344294832016 @default.
• W2534429483 countsByYear W25344294832017 @default.
• W2534429483 countsByYear W25344294832018 @default.
• W2534429483 countsByYear W25344294832019 @default.
• W2534429483 countsByYear W25344294832022 @default.
• W2534429483 countsByYear W25344294832023 @default.
• W2534429483 crossrefType "journal-article" @default.
• W2534429483 hasAuthorship W2534429483A5003493851 @default.
• W2534429483 hasAuthorship W2534429483A5032023438 @default.
• W2534429483 hasAuthorship W2534429483A5032531491 @default.
• W2534429483 hasAuthorship W2534429483A5053831963 @default.
• W2534429483 hasAuthorship W2534429483A5069899816 @default.
• W2534429483 hasConcept C126322002 @default.
• W2534429483 hasConcept C134018914 @default.
• W2534429483 hasConcept C185592680 @default.
• W2534429483 hasConcept C19038510 @default.
• W2534429483 hasConcept C2776091944 @default.
• W2534429483 hasConcept C2776919658 @default.
• W2534429483 hasConcept C2778163477 @default.
• W2534429483 hasConcept C2778657065 @default.
• W2534429483 hasConcept C2778849439 @default.
• W2534429483 hasConcept C2778913445 @default.
• W2534429483 hasConcept C2780072125 @default.
• W2534429483 hasConcept C2781349093 @default.
• W2534429483 hasConcept C43554185 @default.
• W2534429483 hasConcept C543025807 @default.
• W2534429483 hasConcept C55493867 @default.
• W2534429483 hasConcept C71924100 @default.
• W2534429483 hasConceptScore W2534429483C126322002 @default.
• W2534429483 hasConceptScore W2534429483C134018914 @default.
• W2534429483 hasConceptScore W2534429483C185592680 @default.
• W2534429483 hasConceptScore W2534429483C19038510 @default.
• W2534429483 hasConceptScore W2534429483C2776091944 @default.
• W2534429483 hasConceptScore W2534429483C2776919658 @default.
• W2534429483 hasConceptScore W2534429483C2778163477 @default.
• W2534429483 hasConceptScore W2534429483C2778657065 @default.
• W2534429483 hasConceptScore W2534429483C2778849439 @default.
• W2534429483 hasConceptScore W2534429483C2778913445 @default.
• W2534429483 hasConceptScore W2534429483C2780072125 @default.
• W2534429483 hasConceptScore W2534429483C2781349093 @default.
• W2534429483 hasConceptScore W2534429483C43554185 @default.
• W2534429483 hasConceptScore W2534429483C543025807 @default.
• W2534429483 hasConceptScore W2534429483C55493867 @default.
• W2534429483 hasConceptScore W2534429483C71924100 @default.
• W2534429483 hasIssue "1" @default.
• W2534429483 hasLocation W25344294831 @default.

• next